RxSight offers a revolutionary adjustable IOL technology with superior outcomes and reduced side effects compared to traditional IOLs. The company's "razor-and-blade" business model, with the LAL and ...

The company’s fourth quarter and full-year 2025 financial and operational results are preliminary and are subject to the completion of the company’s 2025 audit. Audited full-year 2025 and unaudited ...

CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors, and macroeconomic ...

Sold 27,579 Light Adjustable Lenses, a 36% increase in procedure volume, demonstrating rising demand for its innovative products. Reiterated full-year 2025 revenue guidance of $160.0 million to $175.0 ...

In addition, numerous surgeons will present their LAL experience at the RxSight booth in the convention exhibit hall (Booth #1911). A schedule of these presentations ...

Please provide your email address to receive an email when new articles are posted on . In 2013, Malvina B. Eydelman, MD, director of the FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices, ...

Eye Surgeons Associates is the first practice in Iowa to offer the Light-Adjustable Lens (LAL) by RxSight to cataract patients. Cataracts occur when the eye’s natural lens becomes clouded and rigid, ...

Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...